## **GLOBAL CONSULTATION OF THE WHO-GLI** TB SUPRANATIONAL REFERENCE LABORATORY NETWORK

## Final Agenda

Chair: Christopher Gilpin, WHO Rapporteur: Dick van Soolingen , SRL Netherlands

## WEDNESDAY, 14 APRIL

09:00 - 09:15	Welcome	Karin Weyer, WHO	
09:15 - 09:30	Meeting scope and objectives Review and adoption of meeting agenda	Chris Gilpin, WHO	
Objective 1: To disse	eminate recent developments in WHO policy guidance	e on new methods/tools	
09:30 – 10:00	WHO policy guidance update.	Chris Gilpin, WHO	
10:00 - 10:30	Current draft WHO-CDC biosafety recommendations for TB laboratories	Tom Shinnick,CDC	
BREAK 10:30 – 11:00			
Objective 2: To development of the control of the c	lop revised TORs for the SRLN and discuss eligibility	criteria and a mechanism for	
11:00 – 11:15	GLadMap - Global Laboratory database	May Chu, WHO	
11:15 – 11:30	Overview of SRLN efforts to date	Armand van Deun, SRL Belgium	
11:30- 12:30	Regional perspectives on SRLN requirements, structure and expansion	EMRO, SEARO, WPRO, AFRO, PAHO	
12:30 – 13:00	Discussion	ALL	
LUNCH 13:00 – 14:00			
14:00 – 14:20	The Global Laboratory Initiative Roadmap	Karin Weyer, WHO	
14:20 – 14:40	Expansion of the SRL network in Africa	Armand van Deun, for TBCAP	
14:40 - 15:00	Proposed TORs for the SRLN	Chris Gilpin	
15:00 - 15:30	Discussion	ALL	
BREAK 15:30 – 16:00			
Objective 3: To discuss eligibility criteria and a mechanism for accrediting SRLs			
16:00 - 16:30	Eligibility and inclusion criteria for the SRLN	Chris Gilpin	
16:30 - 17:00	SRL accreditation -What is needed ?	John Ridderhof, GLI Chair	
17:00 - 17:30	Discussion	All	

Chair: John Ridderhof, Chair GLI Rapporteur: Ivan Bastian, SRL Australia

## THURSDAY, 15 APRIL

01 " 1 T		ODI INDI
Objective 4: To revie	w the process for the creation of formal links between	SRLS and NRLS
09:00- 10:00	Summary of Day 1 and consensus to date	Chris Gilpin, WHO
10:00- 10:15	Creation of formal links between SRL and NRLs - What is needed?	Daniela Cirillo, SRL Italy
10:15- 11:00	What support do SRLs need to provide co- ordinated technical assistance to countries?	Discussion session
BREAK 11:00 – 11:30		
	ss requirements and funding mechanisms for SRLs to ordinated technical assistance to countries beyond qua	
11:30 – 11:50	Expanding And Accelerating Access To Diagnostics For Patients At Risk Of Multi-Drug Resistant Tuberculosis (EXPAND-TB) project	C N Paramasivan, FIND
11:50 – 12:15	European Centre for Disease Prevention and Control- European Reference Laboratory Network ECDC-ERLN	Francis Drobniewski, SRL United Kingdom
12:15 - 13:00	Discussion	ALL
LUNCH 13:00 – 14:00		
14:00 – 14:20	SRL technical assistance for drug-resistance surveillance	Matteo Zignol, WHO
14:20 - 14:40	Donor perspectives on SRLN funding (Governmental)	Gavin Macgregor-Skinner, USAID
14:40-15:00	Donor perspectives on SRLN funding (Private sector)	Patrizia Carlevero, Eli Lily
15:00-15:30	Discussion	ALL
BREAK 15:30 – 16:00		
16:00 - 16:30	Co-ordinated technical assistance -The way forward	Chris Gilpin, WHO
16:30 – 17:15	Discussion	ALL
17:15 - 17:30	Next steps	Chris Gilpin, WHO